Dosing and uses of Hydergine (ergoloid mesylates)
Adult dosage forms and strengths
tablet
- 1mg
Age-Related Mental Decline & Alzheimer's Dementia
1 mg PO q8hr
May administer up to 4.5-12 mg/day therapeutic trial should be 6 months in duration
Pediatric dosage forms and strengths
Safety & efficacy not established
Geriatric dosage forms and strengths
Age-Related Mental Decline & Alzheimer's Dementia
1 mg PO q8hr
May administer up to 4.5-12 mg/day therapeutic trial should be 6 months in duration
Hydergine (ergoloid mesylates) adverse (side) effects
Frequency not defined
Flushing
Headache
Rash
Nausea
Vomiting
Nasal congestion
Blurred vision
Bradycardia or bradyarrhythmia
Orthostatic hypotension
Warnings
Contraindications
Hypersensitivity, psychosis; consider other CNS disease before starting
CYP3A4 inhibitors (azole anifungals, protease inhibitors, macrolide antibiotics)
Pregnancy and lactation
Pregnancy category: N/A
Lactation: unknown
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Hydergine (ergoloid mesylates)
Mechanism of action
Contains derivatives of three naturally occurring ergot alkaloids which have some peripheral alpha blocking activity and also depress CNS vasomotor nerve activity resulting in slight decrease in BP and HR; mechanism of action in dementia is largely unknown
Pharmacokinetics
Half-Life elimination: 3.5 hr
Onset: 3-4 wk
Peak Plasma Time: ~1 hr
Concentration: 576 pg/mL
Bioavailability: 9%
Metabolism: Liver